Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating revenue | -2.52%821.8B | -3.82%626.42B | -6.03%420.5B | -3.41%219.84B | -3.73%843.07B | -3.55%651.27B | -2.35%447.49B | -1.09%227.6B | -7.11%875.73B | -5.18%675.22B |
Net interest income | -2.69%637.41B | -4.94%476.73B | -6.84%313.95B | -4.16%161.4B | -5.34%655.01B | -4.72%501.53B | -3.89%336.99B | -4.79%168.41B | 0.19%691.99B | 2.97%526.35B |
-Interest income | 1.63%1.43T | 1.64%1.07T | 3.51%721.05B | 6.40%363.08B | 9.88%1.41T | 11.35%1.06T | 12.50%696.58B | 11.89%341.23B | 10.02%1.28T | 10.60%949.45B |
-Less:Interest expense | 5.40%790.54B | 7.58%597.75B | 13.21%407.1B | 16.70%201.68B | 27.84%750.03B | 31.33%555.64B | 33.88%359.6B | 34.92%172.82B | 24.42%586.69B | 21.82%423.1B |
Net commission income | -8.34%109.4B | -8.98%90.32B | -8.25%67.41B | -2.83%39.34B | -7.71%119.36B | -6.07%99.23B | -3.39%73.47B | -2.86%40.49B | -2.78%129.33B | 0.33%105.64B |
-Commission income | -8.50%126.18B | -8.98%103.09B | -7.27%76.37B | -2.30%43.86B | -5.44%137.89B | -3.36%113.27B | -1.54%82.36B | -1.65%44.9B | -1.96%145.82B | 0.67%117.21B |
-Less:Commission expense | -9.46%16.78B | -9.03%12.77B | 0.79%8.97B | 2.54%4.52B | 12.37%18.53B | 21.32%14.04B | 16.96%8.9B | 11.09%4.41B | 5.03%16.49B | 3.88%11.57B |
Invest income | -10.78%40.93B | -17.35%31.09B | -8.35%21.64B | 5.54%9.2B | 10.53%45.88B | 9.46%37.61B | 5.90%23.61B | -3.86%8.72B | 22.07%41.5B | 30.06%34.36B |
Exchange income | 11.23%-6.91B | 38.04%-4.69B | -3.82%-5.54B | -223.67%-3.9B | -107.27%-7.79B | -217.79%-7.57B | -430.19%-5.34B | -261.18%-1.2B | -205.18%-3.76B | -183.32%-2.38B |
Operating payout | -5.07%400.92B | -5.66%318.93B | -8.39%224.08B | -3.13%117.76B | -6.82%422.31B | -4.19%338.07B | -2.31%244.62B | 0.39%121.57B | -12.71%453.2B | -10.95%352.85B |
Operating and admin expense | 1.41%230.46B | 0.31%156.93B | -0.30%99.45B | 0.60%45.69B | -0.36%227.27B | 1.72%156.44B | 2.40%99.75B | 5.50%45.41B | 0.95%228.09B | 7.66%153.8B |
Operating tax surcharges | 0.97%10.77B | -5.71%7.83B | 0.95%5.55B | 11.04%2.8B | 5.60%10.66B | 14.86%8.3B | 11.79%5.5B | 13.47%2.52B | 8.36%10.1B | 7.21%7.23B |
Credit Impairment Loss | -15.50%125.74B | -12.62%128.95B | -16.60%101.81B | ---- | --148.81B | --147.58B | --122.07B | ---- | ---- | ---- |
Asset Impairment Loss | -53.98%924M | 40.42%337M | 38.30%260M | -7.61%60.08B | -98.90%2.01B | -99.86%240M | -99.86%188M | -8.22%65.02B | -9.84%182.68B | -5.40%169.63B |
Other operating cost | -1.60%33.03B | -2.39%24.9B | -0.61%17.01B | 6.83%9.21B | 3.78%33.57B | 14.96%25.51B | 20.25%17.12B | 72.86%8.62B | -60.22%32.34B | -67.04%22.19B |
Operating profit | 0.03%420.89B | -1.82%307.49B | -3.18%196.42B | -3.72%102.08B | -0.42%420.76B | -2.85%313.2B | -2.39%202.88B | -2.74%106.02B | -0.24%422.53B | 2.06%322.38B |
Add:Nonoperating income | -5.26%1.87B | -3.17%1.25B | 6.81%973M | -17.81%480M | -41.12%1.98B | -54.16%1.3B | -60.78%911M | -68.65%584M | 45.98%3.36B | 195.81%2.83B |
Less:Nonoperating expense | 20.78%930M | 35.57%343M | 55.30%205M | 395.24%104M | -34.13%770M | -65.06%253M | -21.43%132M | -67.19%21M | 21.27%1.17B | 144.59%724M |
Total profit | -0.03%421.83B | -1.86%308.4B | -3.18%197.18B | -3.88%102.46B | -0.65%421.97B | -3.15%314.25B | -3.02%203.66B | -3.81%106.59B | -0.04%424.72B | 2.51%324.48B |
Less:Income tax cost | -3.46%54.88B | -14.42%37.93B | -10.53%25.89B | -9.00%14.39B | -9.20%56.85B | -21.88%44.32B | -22.18%28.94B | -22.81%15.82B | -16.17%62.61B | -10.22%56.73B |
Net profit | 0.50%366.95B | 0.20%270.48B | -1.96%171.3B | -2.98%88.06B | 0.83%365.12B | 0.81%269.93B | 1.10%174.72B | 0.50%90.77B | 3.40%362.11B | 5.69%267.75B |
Less:Minority Profit | -3.56%1.08B | 15.45%1.45B | -15.06%829M | -32.51%409M | 14.83%1.12B | 6.17%1.26B | -15.06%976M | 256.47%606M | -47.92%978M | -21.60%1.18B |
Net profit of parent company owners | 0.51%365.86B | 0.13%269.03B | -1.89%170.47B | -2.78%87.65B | 0.79%363.99B | 0.79%268.67B | 1.21%173.74B | 0.02%90.16B | 3.67%361.13B | 5.86%266.57B |
Earning per share | ||||||||||
Basic earning per share | 0.00%0.98 | 0.00%0.72 | -2.08%0.47 | -4.00%0.24 | 1.03%0.98 | 0.00%0.72 | 2.13%0.48 | 0.00%0.25 | 2.11%0.97 | 4.35%0.72 |
Diluted earning per share | 0.00%0.98 | 0.00%0.72 | -2.08%0.47 | -4.00%0.24 | 1.03%0.98 | 0.00%0.72 | 2.13%0.48 | 0.00%0.25 | 2.11%0.97 | 4.35%0.72 |
Other composite income | 166.23%51.19B | 142.22%25.5B | 58.84%28.75B | 438.89%12.92B | 522.57%19.23B | 404.36%10.53B | 361.74%18.1B | 65.01%-3.81B | 44.32%-4.55B | 2,032.41%2.09B |
Other composite income of parent company owners | 162.89%52.39B | 133.46%26.21B | 62.05%29.06B | 439.52%13.87B | 534.73%19.93B | 571.01%11.23B | 347.90%17.93B | 62.70%-4.08B | 44.43%-4.58B | 814.96%1.67B |
Other composite income of minority owners | -71.18%-1.2B | -1.71%-712M | -287.35%-311M | -448.35%-951M | -2,161.76%-701M | -269.08%-700M | -47.96%166M | 378.95%273M | -55.84%34M | 228.57%414M |
Total composite income | 8.79%418.14B | 5.53%295.97B | 3.75%200.05B | 16.12%100.98B | 7.49%384.34B | 3.94%280.46B | 16.22%192.82B | 9.49%86.96B | 4.54%357.56B | 6.56%269.84B |
Total composite income of parent company owners | 8.94%418.25B | 5.48%295.23B | 4.10%199.53B | 17.94%101.52B | 7.68%383.92B | 4.35%279.9B | 16.57%191.68B | 8.69%86.08B | 4.84%356.55B | 6.62%268.24B |
Total composite income of minority owners | -127.73%-117M | 32.73%738M | -54.64%518M | -161.66%-542M | -58.30%422M | -65.18%556M | -22.21%1.14B | 287.22%879M | -48.24%1.01B | -2.32%1.6B |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
Auditor | Ernst & Young Huaming Certified Public Accountants (Special General Partnership) | -- | -- | -- | Deloitte Huayong Certified Public Accountants (Special General Partnership) | -- | -- | -- | Deloitte Huayong Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.